Day: January 29, 2024

MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade imaging Real World Data (“iRWD”), today announced its participation as an exhibitor at the 15th Annual SCOPE Summit for Clinical Ops Executive (the “SCOPE Summit”) being held February 11-14, 2024 in Orlando, FL. OneMedNet’s Founder and Chief Medical Officer Jeffrey Yu, President Aaron Green, and senior team members, will be on-site to discuss OneMedNet’s iRWDTM solution at the SCOPE Summit’s Real World Evidence track, available at Booth 228. The 2024 SCOPE Summit will feature two Real World Evidence tracks that highlight the critical importance and innovative science and technology of this specialized data: Accessing and Generating RWD and Leveraging RWD for Clinical Research...

PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer access discontinued OSA devices. Earlier in January, Philips Respironics announced the discontinuation of many devices used for the treatment and diagnosis of sleep apnea, including CPAP systems. This discontinuation follows several U.S. Food and Drug Administration (FDA) mandated CPAP recalls over the past several years adversely impacting an estimated 4 million patients. ProSomnus precision intraoral devices have demonstrated excellent efficacy, adherence, and patient preference in numerous clinical studies, including a head-to-head cross over study...

Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and Degeneration 2024 Conference on Saturday, February 3, 2024 during Session VI (3:30 to 5:00 p.m. ET) Company to host webcast on Monday, February 5, 2024 at 8:00 a.m. ETEMERYVILLE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that it will host a live webcast to discuss interim data from the intravitreal 4D-150 Phase 2 PRISM clinical trial in wet AMD patients with severe disease activity and high treatment burden, as...

REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer. Dr. Corbau will serve as a member of Adverum’s executive committee. “On behalf of the entire team at Adverum, I am delighted to welcome Dr. Corbau as the newest member of our executive leadership team. Romu has spent the majority of his career working to deliver on the promise of gene therapy. Earlier in his career, Romu led Spark Therapeutics’ translational R&D for Luxturna®, a subretinal injection gene therapy product for Leber’s congenital amaurosis, an inherited form of vision loss that...

CONSHOHOCKEN, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced three new members of its leadership team: Mark Barrett joins Madrigal as Chief Business Officer, Clint Wallace joins as Chief Human Resources Officer and Tina Ventura joins as Chief Investor Relations Officer. “I am delighted to welcome Mark, Clint and Tina to the team,” said Bill Sibold, Chief Executive Officer of Madrigal. “As we prepare for a first-to-market launch of resmetirom in NASH with significant fibrosis, we are also building a foundation for enduring leadership. These new leaders are not only experts in their respective areas but have experience scaling teams and organizations. They will each play...

U.S. patent allowance impacts Aging-related Frailty patients receiving vaccines and builds upon a growing patent estate protecting the use of Lomecel-B™ MIAMI, Jan. 29, 2024 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions , today announces it received a notice of patent allowance from the United States Patent and Trademark Office (PTO) for Medicinal Signaling Cells (MSCs), the technology behind its lead investigational product Lomecel-BTM . The allowance impacts patients with Aging-related Frailty receiving vaccines for conditions such as Covid and the flu. The new U.S. patent adds to the intellectual property from previous patents issued to Longeveron in the European...

LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that three abstracts will be presented from the KER-012 program at the Pulmonary Vascular Research Institute (“PVRI”) 2024 Annual Congress, to be held from January 31 through February 3, 2024. Clinical Presentations “Development of KER-012, a Novel Investigational Activin Receptor Type IIB Ligand Trap with High Activin/GDF Specificity and Target Engagement for the Treatment of Pulmonary Arterial Hypertension: Rationale and Design of the TROPOS...

Beijing, Jan. 29, 2024 (GLOBE NEWSWIRE) — WiMi Hologram Cloud Inc. (NASDAQ: WIMI) (“WiMi” or the “Company”), a leading global Hologram Augmented Reality (“AR”) Technology provider, today announced that it has been focusing on solving the bottleneck of holographic head-mounted display technology, challenging the traditional display mode and enhancing the overall user experience. WiMi’s HoloAR Lens was developed by using a holographic eye-tracking focusing system, an optical system with adjustable pupil distance, and real-time FOV digital control in a product that involves optical engineering, computer vision, human-computer interaction, etc. The core innovation of the HoloAR Lens is that WiMi developed a holographic eye-tracking focusing system. It uses advanced computer vision technology...